These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 32630281)

  • 1. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.
    Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
    Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    Fleury H; Malaquin N; Tu V; Gilbert S; Martinez A; Olivier MA; Sauriol SA; Communal L; Leclerc-Desaulniers K; Carmona E; Provencher D; Mes-Masson AM; Rodier F
    Nat Commun; 2019 Jun; 10(1):2556. PubMed ID: 31186408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.
    Cheng J; Moore S; Gomez-Galeno J; Lee DH; Okolotowicz KJ; Cashman JR
    J Pharmacol Exp Ther; 2019 Dec; 371(3):703-712. PubMed ID: 31582422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
    Wang Z; Gao J; Zhou J; Liu H; Xu C
    J Gynecol Oncol; 2019 Mar; 30(2):e26. PubMed ID: 30740957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer.
    Carpenter V; Saleh T; Chakraborty E; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2024 Aug; 226():116385. PubMed ID: 38909784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
    Gewirtz DA; Alotaibi M; Yakovlev VA; Povirk LF
    Radiat Res; 2016 Oct; 186(4):327-332. PubMed ID: 27588595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.
    Ghorai A; Mahaddalkar T; Thorat R; Dutt S
    Cancer Lett; 2020 Oct; 490():44-53. PubMed ID: 32645394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
    McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
    Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.
    Pungsrinont T; Sutter MF; Ertingshausen MCCM; Lakshmana G; Kokal M; Khan AS; Baniahmad A
    Cell Biosci; 2020; 10():59. PubMed ID: 32351687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting Markers of Therapy-Induced Senescence in Cancer Cells.
    Fan DN; Schmitt CA
    Methods Mol Biol; 2017; 1534():41-52. PubMed ID: 27812866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.
    Tchelougou D; Malaquin N; Cardin GB; Desmul J; Turcotte S; Rodier F
    Front Cell Dev Biol; 2024; 12():1368711. PubMed ID: 38946802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice.
    Ray SD; Balasubramanian G; Bagchi D; Reddy CS
    Free Radic Biol Med; 2001 Aug; 31(3):277-91. PubMed ID: 11461765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
    Burdova K; Storchova R; Palek M; Macurek L
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.